Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Trade with 70% Backtested Accuracy
Analyst Views on IMTX
About IMTX
About the author
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
Immatics Names Venkat Ramanan as Chief Financial Officer
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan as Chief Financial Officer, effective immediately, succeeding Arnd Christ.
Ramanan's Background: Venkat Ramanan brings over 25 years of experience in the biopharmaceutical industry, having previously served as CFO at Anthos Therapeutics, a Novartis company.
Stock Performance: Following the announcement, Immatics' stock closed 7.71% higher at $8.52 on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Immatics Names Venkat Ramanan as CFO
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, succeeding Arnd Christ. Dr. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles at companies like Seagen, Gilead Sciences, and Amgen.
Focus on PRAME Cell Therapy: Dr. Ramanan's expertise will support Immatics in advancing its PRAME cell therapy, anzu-cel, towards commercialization, particularly for patients with metastatic melanoma, as the company aims to strengthen its position as a leader in precision targeting of PRAME.
Guggenheim Begins Coverage of Immatics N.V. (IMTX) with a Buy Rating
Guggenheim Coverage Initiation: Guggenheim initiated coverage of Immatics N.V. with a "Buy" recommendation on September 18, 2025, projecting a 113.83% upside based on an average one-year price target of $14.13/share.
Institutional Ownership Trends: There are currently 109 funds reporting positions in Immatics N.V., with a 14.17% decrease in owners over the last quarter, while total shares owned by institutions increased by 1.26% to 98,918K shares.
Significant Shareholder Increases: Major shareholders like T. Rowe Price, Suvretta Capital, and Baker Bros. Advisors have significantly increased their holdings in Immatics N.V. over the last quarter, with increases ranging from 19.92% to 46.16%.
Bullish Market Sentiment: The put/call ratio for IMTX is 0.19, indicating a bullish outlook among investors, despite a decrease in the number of funds holding shares.
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
Immatics Names Venkat Ramanan as Chief Financial Officer
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan as Chief Financial Officer, effective immediately, succeeding Arnd Christ.
Ramanan's Background: Venkat Ramanan brings over 25 years of experience in the biopharmaceutical industry, having previously served as CFO at Anthos Therapeutics, a Novartis company.
Stock Performance: Following the announcement, Immatics' stock closed 7.71% higher at $8.52 on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Immatics Names Venkat Ramanan as CFO
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, succeeding Arnd Christ. Dr. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles at companies like Seagen, Gilead Sciences, and Amgen.
Focus on PRAME Cell Therapy: Dr. Ramanan's expertise will support Immatics in advancing its PRAME cell therapy, anzu-cel, towards commercialization, particularly for patients with metastatic melanoma, as the company aims to strengthen its position as a leader in precision targeting of PRAME.
Guggenheim Begins Coverage of Immatics N.V. (IMTX) with a Buy Rating
Guggenheim Coverage Initiation: Guggenheim initiated coverage of Immatics N.V. with a "Buy" recommendation on September 18, 2025, projecting a 113.83% upside based on an average one-year price target of $14.13/share.
Institutional Ownership Trends: There are currently 109 funds reporting positions in Immatics N.V., with a 14.17% decrease in owners over the last quarter, while total shares owned by institutions increased by 1.26% to 98,918K shares.
Significant Shareholder Increases: Major shareholders like T. Rowe Price, Suvretta Capital, and Baker Bros. Advisors have significantly increased their holdings in Immatics N.V. over the last quarter, with increases ranging from 19.92% to 46.16%.
Bullish Market Sentiment: The put/call ratio for IMTX is 0.19, indicating a bullish outlook among investors, despite a decrease in the number of funds holding shares.
